How much will patients have to pay after Platinib is included in medical insurance?

Pralsetinib is a targeted therapy drug, mainly suitable for the treatment of non-small cell lung cancer (NSCLC) with positive RET gene rearrangements, and is also approved for other tumor types carrying RET gene mutations, including certain thyroid cancers and other solid tumors. This makes platinib an important role in cancer treatment, especially for patients who have received other treatments but failed to respond, providing new treatment hope. By inhibiting the activity of RET tyrosine kinase, Platinib can effectively prevent the growth and spread of cancer cells, thereby improving patients' survival rate and quality of life.

Although platinib, a new anti-cancer drug, has been launched in China, unfortunately it has not yet been included in the medical insurance system, which has caused a certain financial burden to many patients. The common packaging specification of its original drug is 100mg, and each bottle provides 60 or 120 tablets. Depending on market conditions, the price of a box of Platinib may be as high as 20,000 yuan, and even as high as 60,000 yuan in some areas. This poses great pressure to many patients, especially those with limited financial resources.

In response to this problem, patients expect platinib to be included in the medical insurance system as soon as possible. If it is successfully included in medical insurance in 2025, it is expected that patients' out-of-pocket expenses will be significantly reduced, and the specific expenses will be determined according to the formulation of medical insurance policies. Usually, after being included in medical insurance, patients only need to bear a certain proportion of out-of-pocket expenses, which may range from a few thousand to ten thousand yuan, depending on the proportion of medical insurance reimbursement and the type of personal medical insurance.

In addition, generic drugs of Platinib are also available in overseas markets. The drug has similar ingredients to the original drug. For example, the generic drug produced in Laos costs about more than 3,000 yuan for 120 pills, which has significant economic advantages compared to the original drug. This development provides patients with more choices, especially when the price of original drugs is high, and generic drugs will become an affordable option for patients.

Reference: https://gavreto.com/